A senior government official in the Philippines announced the launch of a major clinical trial investigating several drugs including ivermectin, the anti-parasite medication used frequently in the tropics, in patients with COVID-19 in a quest to determine safety and efficacy. While ivermectin has grown in popularity here as an off-label treatment for COVID-19, the majority of world drug regulators and government research bodies believe the existing clinical trial data isn’t sufficient for any emergency use authorization declaration. That’s the same here in the Philippines as the food and drug regulator in this Southeastern Asian nation cautions against use for the SARS-CoV-2 indication due to the lack of evidence. Fortunato de la Pena, the nation’s science and technology minister, declared in a presentation Monday that the ivermectin-focused clinical trial “will give us a more reliable estimate of the effects of ivermectin as an antiviral agent in mild and moderate (COVID-19) patients.”
With over 945,000 COVID-19 cases and more than 16,000 deaths, this country is on the edge as early on its didn’t face that great of a disruption from the pandemic—unlike count...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).